PHARMACEUTICAL COMPOSITIONS COMPRISING A PSYCHEDELIC DRUG AND A DENDRITIC NANOCARRIER

The present invention relates to formulations for administration of a psychedelic drug such as psilocin, lysergide (lysergic acid diethylamide, LSD), mescaline, ketamine or 3,4-meth-ylendioxy-N-methylamphetamine (MDMA). It provides a composition comprising a psychedelic drug and at least one hyperbranched dendritic core-multishell-nanocarrier or core-shell nanocarrier, such as a hyperbranched dendritic polyglycerol nanocarrier, as well as corresponding pharmaceutical compositions and methods of preparing the same. Preferably, the psychedelic drug, e.g., psilocin, is stabilized by the composition of the invention, and/or its transdermal or transmucosal bioavailability is enhanced. The pharmaceutical composition can be for use in the therapy of e.g., a mental disorder selected from the group comprising depression such as major depressive disorder, treatment-resistant depression or depression linked to terminal illness, anxiety, obsessive-compulsive disorder, bipolar disorder and post-traumatic stress disorder, or in treating drug dependence (e.g., alcoholism or tobacco addiction), pain, cluster headaches, status epilepticus or Parkinson's disease.